Skip To Main Content
Christopher P. Venner on Muck Rack

Christopher P. Venner

As seen in: Nature, JACC (Journal of the American College of Cardiology), Canadian Journal of Cardiology, Journal of Cardiac Failure
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Christopher P. Venner’s profile

Articles by Christopher P. Venner

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

|
By Thierry Facon, Gordon Cook, Saad Usmani, Cyrille Hulin, Shaji Kumar Verified, Cyrille Touzeau, Nizar Bahlis, Supratik Basu, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty Verified, Christopher P. Venner, Katja Weisel, Noopur Raje, Salomon Manier, Mai T. Ngo, Kasey Bolyard, Fredrik Borgsten, Robin Carson, Sonja Zweegman, Marjohn Armoon
| Nature Verified
Abstract In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Here, we report an updated subgroup analysis by frailty status.
Open in Who Shared Issue with article?

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

|
By Thierry Facon, Shaji Kumar Verified, Robert Orlowski, Nizar Bahlis, Philippe Moreau, Hartmut Goldschmidt, Supratik Basu, Cyrille Hulin, Sonja Zweegman, Katja Weisel, Aurore Perrot, Caroline Jacquet, Noopur Raje, Salomon Manier, Ajai Chari, Markus Hansson, Mohamad Mohty Verified, Michel Delforge, Torben Plesner, Gordon Cook, Xavier Leleu, Hang Quach, Christopher P. Venner, Mourad Tiab, Margaret Macro, Laurent Frenzel, George Wang, Huiling Pei, Robin Carson, Fredrik Borgsten, Saad Usmani, Kasey Bolyard
| Nature Verified
Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report results on long-term OS and subsequent antimyeloma therapies from the MAIA final analysis. A protocol amendment (July 20, 2021) led to a long-term extension of MAIA, during which patients were followed for OS.
Open in Who Shared Issue with article?

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

|
By Sonja Zweegman, Saad Usmani, Vânia Hungria, Nizar Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep Marti, Supratik Basu, Yael Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Angelo Maiolino, Mai T. Ngo, Fredrik Borgsten, Melissa Rowe, Robin Carson, Thierry Facon, Lorena Lopez-Masi
| Nature Verified
To the Editor Daratumumab, lenalidomide, and dexamethasone (DRd) is approved to treat transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) based on the phase 3 MAIA trial [1,2,3]. Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) is approved to treat patients with NDMM, regardless of autologous stem-cell transplant eligibility, based on the phase 3 PERSEUS [4] and CEPHEUS [5] trials. Outcomes in frail patients from CEPHEUS are unknown.
Open in Who Shared Issue with article?

Resolution of Cardiac Infiltration Following Autologous Stem Cell Transplantation for AL Amyloidosis:

|
By Kai Wu, Craig Butler, Christopher P. Venner, D. Ian Paterson
| JACC (Journal of the American College of Cardiology)
History of Presentation A 43-year-old man presented to the emergency department with shortness of breath of 6 months’ duration. He previously played ice hockey regularly, but now experienced NYHA functional class III dyspnea. He had no associated chest pain, cough, orthopnea, or paroxysmal nocturnal dyspnea. His blood pressure was 114/82 mm Hg, heart rate was 105 beats/min, and oxygen saturation was 94% on room air.
Open in Who Shared Issue with article?

The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada

|
By Nariman Sepehrvand, Erik Youngson, Christopher P. Venner, Ian Paterson
| Journal of Cardiac Failure Verified
Abstract Background Despite the improved awareness of cardiac amyloidosis among clinicians, its incidence and prevalence is not well-described in a community setting. We sought to investigate the incidence and prevalence of cardiac amyloidosis in the community.
Open in Who Shared Issue with article?

A Descriptive Cost‐Analysis of MYX.1/MCRN003, a Phase 2 Clinical Trial Evaluating High‐dose Weekly Carfilzomib, Cyclophosphamide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

|
By Christopher P. Venner, Matthew Cheung, Joe Pater, Bethany E. Monteith
| Wiley Online Library Verified
ORIGINAL ARTICLE Bethany E. Monteith, Corresponding Author bemonteith@gmail.com Bethany.Monteith@queensu.ca orcid.org/0000-0001-7692-1947 Queen's University, Canadian Cancer Trials Group, Kingston, Ontario, Canada Queen's University, Cancer Center of Southeastern Ontario, Kingston, Ontario, Canada Corresponding Author Bethany E.
Open in Who Shared Issue with article?

Cardiac Rehabilitation in Lymphoma Patients undergoing Autologous Hematopoietic Stem Cell Transplantation: A Cardio-Oncology Pilot Project

|
By Derek Rothe, Nanette Cox-Kennett, David M. Buijs, Christopher P. Venner
| Canadian Journal of Cardiology Verified
Publication HistoryPublished online: July 12, 2018Accepted: July 3, 2018; Received in revised form: June 26, 2018; Received: May 16, 2018;
Open in Who Shared Issue with article?
Show More